CoChat
Sign Up
Cited by 57Antifungal resistance and susceptibilityvaccines and immunoinformatics approachesBacterial biofilms and quorum sensing

The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection

Open access
Uppuluri, Priya, Lin, Lin, Alqarihi, Abdullah, Luo, Guanpingsheng, Youssef, Eman G., Alkhazraji, Sondus, Yount, Nannette Y., Ibrahim, Belal A. +6 more·2018·PLOS Pathogens
DOI 10.1371/journal.ppat.1007056PMC PMC5963808
Open this paper in CoChat — free accountOpen PDF

Abstract

Different pathogens share similar medical settings and rely on similar virulence strategies to cause infections. We have previously applied 3-D computational modeling and bioinformatics to discover novel antigens that target more than one human pathogen. Active and passive immunization with the recombinant N-terminus of Candida albicans Hyr1 (rHyr1p-N) protect mice against lethal candidemia. Here we determine that Hyr1p shares homology with cell surface proteins of the multidrug resistant Gram negative bacterium, Acinetobacter baumannii including hemagglutinin (FhaB) and outer membrane protein A (OmpA). The A. baumannii OmpA binds to C. albicans Hyr1p, leading to a mixed species biofilm. Deletion of HYR1, or blocking of Hyr1p using polyclonal antibodies, significantly reduce A. baumannii binding to C. albicans hyphae. Furthermore, active vaccination with rHyr1p-N or passive immunization with polyclonal antibodies raised against specific peptide motifs of rHyr1p-N markedly improve survival of diabetic or neutropenic mice infected with A. baumannii bacteremia or pneumonia. Antibody raised against one particular peptide of the rHyr1p-N sequence (peptide 5) confers majority of the protection through blocking A. baumannii invasion of host cells and inducing death of the bacterium by a putative iron starvation mechanism. Anti-Hyr1 peptide 5 antibodies also mitigate A. baumannii /C. albicans mixed biofilm formation in vitro. Consistent with our bioinformatic analysis and structural modeling of Hyr1p, anti-Hyr1p peptide 5 antibodies bound to A. baumannii FhaB, OmpA, and an outer membrane siderophore binding protein. Our studies highlight the concept of cross-kingdom vaccine protection against high priority human pathogens such as A. baumannii and C. albicans that share similar ecological niches in immunocompromised patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1007056

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 81

  1. [1]Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(10): 3471– 84. Epub 2007/07/25. doi: 10.1128/AAC.01464-06 17646423 PMC2043292 · DOI
  2. [2]Maragakis LL, Tucker MG, Miller RG, Carroll KC, Perl TM. Incidence and prevalence of multidrug-resistant acinetobacter using targeted active surveillance cultures. Jama. 2008; 299(21): 2513– 4. Epub 2008/06/05. doi: 10.1001/jama.299.21.2513 18523219 · DOI
  3. [3]Maragakis LL, Winkler A, Tucker MG, Cosgrove SE, Ross T, Lawson E, et al Outbreak of multidrug-resistant Serratia marcescens infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2008; 29(5): 418– 23. Epub 2008/04/19. doi: 10.1086/587969 18419363 · DOI
  4. [4]Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006; 43 Suppl 2: S43– 8. Epub 2006/08/09. doi: 10.1086/504476 16894514 · DOI
  5. [5]Aronson NE, Sanders JW, Moran KA. In harm’s way: infections in deployed American military forces. Clin Infect Dis. 2006; 43(8): 1045– 51. Epub 2006/09/20. doi: 10.1086/507539 16983619 · DOI
  6. [6]Harman DR, Hooper TI, Gackstetter GD. Aeromedical evacuations from Operation Iraqi Freedom: a descriptive study. Mil Med. 2005; 170(6): 521– 7. Epub 2005/07/09. 16001605
  7. [7]Hinsley DE, Phillips SL, Clasper JS. Ballistic fractures during the 2003 Gulf conflict—early prognosis and high complication rate. J R Army Med Corps. 2006; 152(2): 96– 101. Epub 2006/12/21. 17175773
  8. [8]Murray CK, Roop SA, Hospenthal DR, Dooley DP, Wenner K, Hammock J, et al Bacteriology of war wounds at the time of injury. Mil Med. 2006; 171(9): 826– 9. Epub 2006/10/14. 17036599
  9. [9]Murray CK, Yun HC, Griffith ME, Thompson B, Crouch HK, Monson LS, et al Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med. 2009; 174(6): 598– 604. Epub 2009/07/10. 19585772
  10. [10]Perez F, Hujer AM, Hulten EA, Fishbain J, Hujer KM, Aron D, et al Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am J Infect Control. 38(1): 63– 5. Epub 2009/09/29. doi: 10.1016/j.ajic.2009.05.007 19783325 PMC4085753 · DOI
  11. [11]Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, et al Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 52 Suppl 5: S397– 428. Epub 2011/04/16. doi: 10.1093/cid/cir153 21474585 PMC3738230 · DOI
  12. [12]Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther. 2008; 6(1): 39– 49. Epub 2008/02/07. doi: 10.1586/14787210.6.1.39 18251663 · DOI
  13. [13]Talbot GH, Bradley J, Edwards JE Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006; 42(5): 657– 68. Epub 2006/02/01. doi: 10.1086/499819 16447111 · DOI
  14. [14]Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1): 1– 12. Epub 2008/11/28. doi: 10.1086/595011 19035777 · DOI
  15. [15]Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis. 42(10): 741– 6. Epub 2010/05/27. doi: 10.3109/00365548.2010.489568 20500117 · DOI
  16. [16]Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother. 2009; 63(4): 775– 80. Epub 2009/01/23. doi: 10.1093/jac/dkn555 19158109 · DOI
  17. [17]Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008; 8(12): 751– 62. Epub 2008/11/22. doi: 10.1016/S1473-3099(08)70279-2 19022191 · DOI
  18. [18]Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 50(2): 229– 38. Epub 2009/12/23. doi: 10.1086/648720 20025527 · DOI
  19. [19]Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochimica et Biophysica Acta. 1984; 770(2): 230– 4. Epub 1984/03/14. 6696909
  20. [20]Park YK, Jung SI, Park KH, Cheong HS, Peck KR, Song JH, et al Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis. 2009; 64(1): 43– 51. Epub 2009/04/14. doi: 10.1016/j.diagmicrobio.2009.01.012 19362258 · DOI
  21. [21]Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009; 53(9): 3628– 34. Epub 2009/06/17. doi: 10.1128/AAC.00284-09 19528270 PMC2737849 · DOI
  22. [22]Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. 2008; 32(5): 450– 4. Epub 2008/09/05. doi: 10.1016/j.ijantimicag.2008.05.016 18768302 · DOI
  23. [23]Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999; 28(5): 1008– 11. Epub 1999/08/19. doi: 10.1086/514732 10452626 · DOI
  24. [24]Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008; 61(6): 1369– 75. Epub 2008/03/28. doi: 10.1093/jac/dkn128 18367459 · DOI
  25. [25]Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2009; 15(6): 980– 2. Epub 2009/06/16. doi: 10.3201/eid1506.081006 19523312 PMC2727341 · DOI
  26. [26]Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernandez-Cuenca F, et al Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009; 30(3): 257– 63. Epub 2009/02/10. doi: 10.1086/595977 19199531 · DOI
  27. [27]Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases. 2014; 2(12): 787– 814. doi: 10.12998/wjcc.v2.i12.787 25516853 PMC4266826 · DOI
  28. [28]Vidal R, Dominguez M, Urrutia H, Bello H, Garcia A, Gonzalez G, et al Effect of imipenem and sulbactam on sessile cells of Acinetobacter baumannii growing in biofilm. Microbios. 1997; 91(367): 79– 87. 9467922
  29. [29]Mietto C, Pinciroli R, Patel N, Berra L. Ventilator associated pneumonia: evolving definitions and preventive strategies. Respir Care. 2013; 58(6): 990– 1007. doi: 10.4187/respcare.02380 23709196 · DOI
  30. [30]Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, et al Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care. 2012; 16(3): R93 doi: 10.1186/cc11357 22621676 PMC3580639 · DOI
  31. [31]Liao YT, Kuo SC, Lee YT, Chen CP, Lin SW, Shen LJ, et al Sheltering effect and indirect pathogenesis of carbapenem-resistant Acinetobacter baumannii in polymicrobial infection. Antimicrob Agents Chemother. 2014; 58(7): 3983– 90. doi: 10.1128/AAC.02636-13 24798276 PMC4068520 · DOI
  32. [32]Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3): 538– 82. Epub 2008/07/16. doi: 10.1128/CMR.00058-07 18625687 PMC2493088 · DOI
  33. [33]Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med. 2006; 145(8): 582– 91. 17043340
  34. [34]Sebeny PJ, Riddle MS, Petersen K. Acinetobacter baumannii skin and soft-tissue infection associated with war trauma. Clin Infect Dis. 2008; 47(4): 444– 9. doi: 10.1086/590568 18611157 · DOI
  35. [35]Gaddy JA, Tomaras AP, Actis LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun. 2009; 77(8): 3150– 60. Epub 2009/05/28. doi: 10.1128/IAI.00096-09 19470746 PMC2715673 · DOI
  36. [36]Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC Jr., Mylonakis E. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2008; 105(38): 14585– 90. doi: 10.1073/pnas.0805048105 18794525 PMC2567192 · DOI
  37. [37]Kostoulias X, Murray GL, Cerqueira GM, Kong JB, Bantun F, Mylonakis E, et al Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology. Antimicrob Agents Chemother. 2015; 60(1): 161– 7. doi: 10.1128/AAC.01540-15 26482299 PMC4704244 · DOI
  38. [38]Yeaman MR, Filler SG, Schmidt CS, Ibrahim AS, Edwards JE Jr., Hennessey JP Jr. Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus. Front Immunol. 2014; 5: 463 doi: 10.3389/fimmu.2014.00463 25309545 PMC4176462 · DOI
  39. [39]Yeaman MR, Filler SG, Chaili S, Barr K, Wang H, Kupferwasser D, et al Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proc Natl Acad Sci U S A. 2014; 111(51): E5555– 63. doi: 10.1073/pnas.1415610111 25489065 PMC4280579 · DOI
  40. [40]Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009; 5(12): e1000703 Epub 2009/12/31. doi: 10.1371/journal.ppat.1000703 20041174 PMC2792038 · DOI
  41. [41]Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, et al The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun. 2008; 76(10): 4574– 80. Epub 2008/07/23. doi: 10.1128/IAI.00700-08 18644876 PMC2546811 · DOI
  42. [43]Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol. 2009 Epub 2009/01/23. doi: 10.1111/j.1574-695X.2008.00531.x 19159425 PMC2801022 · DOI
  43. [44]Spellberg B, Ibrahim AS, Lin L, Avanesian V, Fu Y, Lipke P, et al Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis. 2008; 197(7): 967– 71. Epub 2008/04/19. doi: 10.1086/529204 18419471 PMC2717621 · DOI
  44. [45]Yeaman M, Filler S, Chaili S, Barr K, Wang H, Kupferwasser D, et al., editors. Efficacy and Immunologic Mechanisms of NDV-3 Vaccine in a Murine Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Skin / Skin Structure Infection (SSSI). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2012; San Francisco, CA.
  45. [46]Yeaman MR, Ibrahim AS, Filler SG, Chaili S, Barr K, Wang H, et al., editors. Efficacy of NDV3 vaccine in a murine model of Staphylococcus aureus skin / soft tissue infection (SSTI). Gordon Research Conference on Staphylococcal Diseases; 2011; Barga, Italy.
  46. [47]Lee IM, Tu IF, Yang F-L, Ko T-P, Liao J-H, Lin N-T, et al Structural basis for fragmenting the exopolysaccharide of Acinetobacter baumannii by bacteriophage ΦAB6 tailspike protein. Scientific Reports. 2017; 7: 42711 https://www.nature.com/articles/srep42711#supplementary-information. 28209973 PMC5314372
  47. [48]Darwish Alipour Astaneh S, Rasooli I, Mousavi Gargari SL. Filamentous hemagglutinin adhesin FhaB limits A.baumannii biofilm formation. Front Biosci (Elite Ed). 2017; 9: 266– 75. 28199190
  48. [49]Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis. 2010; 201(11): 1718– 28. Epub 2010/04/27. doi: 10.1086/652407 20415594 PMC3933264 · DOI · Paper page
  49. [51]Luo G, Spellberg B, Gebremariam T, Bolaris M, Lee H, Fu Y, et al Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother. Epub 2012/03/06. doi: 10.1093/jac/dks050 22389456 PMC3584961 · DOI
  50. [52]Brand A, Barnes JD, Mackenzie KS, Odds FC, Gow NA. Cell wall glycans and soluble factors determine the interactions between the hyphae of Candida albicans and Pseudomonas aeruginosa. FEMS Microbiol Lett. 2008; 287(1): 48– 55. doi: 10.1111/j.1574-6968.2008.01301.x 18680523 PMC2613227 · DOI · Paper page
  51. [53]Luo G, Ibrahim AS, French SW, Edwards JE Jr., Fu Y. Active and Passive Immunization with rHyr1p-N Protects Mice against Hematogenously Disseminated Candidiasis. PLoS One. 2011; 6(10): e25909 doi: 10.1371/journal.pone.0025909 22028796 PMC3189951 · DOI · Paper page
  52. [54]Alsultan AA, Hamouda A, Evans BA, Amyes SG. Acinetobacter baumannii: emergence of four strains with novel bla(OXA-51-like) genes in patients with diabetes mellitus. J Chemother. 2009; 21(3): 290– 5. Epub 2009/07/02. doi: 10.1179/joc.2009.21.3.290 19567349 · DOI
  53. [55]Choi CH, Lee JS, Lee YC, Park TI, Lee JC. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 2008; 8: 216 Epub 2008/12/11. doi: 10.1186/1471-2180-8-216 19068136 PMC2615016 · DOI
  54. [56]Darvish Alipour Astaneh S, Rasooli I, Mousavi Gargari SL. The role of filamentous hemagglutinin adhesin in adherence and biofilm formation in Acinetobacter baumannii ATCC19606T. Microbial Pathogenesis. 2014; 74(Supplement C): 42– 9. https://doi.org/10.1016/j.micpath.2014.07.007. 25086432 · DOI
  55. [57]Pérez A, Merino M, Rumbo-Feal S, Álvarez-Fraga L, Vallejo JA, Beceiro A, et al The FhaB/FhaC two-partner secretion system is involved in adhesion of Acinetobacter baumannii AbH12O-A2 strain. Virulence. 2017; 8(6): 959– 74. doi: 10.1080/21505594.2016.1262313 27858524 PMC5626241 · DOI
  56. [58]Nwugo C, Gaddy JA, Zimbler DL, Actis LA. Deciphering the iron response in Acinetobacter baumannii: a proteomics approach. Journal of proteomics. 2011; 74(1): 44– 58. doi: 10.1016/j.jprot.2010.07.010 20692388 PMC2997898 · DOI
  57. [59]Zimbler DL, Arivett BA, Beckett AC, Menke SM, Actis LA. Functional Features of TonB Energy Transduction Systems of Acinetobacter baumannii. Infection and Immunity. 2013; 81(9): 3382– 94. doi: 10.1128/IAI.00540-13 23817614 PMC3754232 · DOI
  58. [60]Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev. 1999; 12(3): 394– 404. 10398672 PMC100245
  59. [62]Tan X, Zhu S, Yan D, Chen W, Chen R, Zou J, et al Candida spp. airway colonization: A potential risk factor for Acinetobacter baumannii ventilator-associated pneumonia. Med Mycol. 2016; 54(6): 557– 66. doi: 10.1093/mmy/myw009 27001670 · DOI
  60. [63]Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, et al Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One. 7(1): e29446 Epub 2012/01/19. doi: 10.1371/journal.pone.0029446 22253723 PMC3254619 · DOI
  61. [64]Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, et al Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine. 2013; 31(2): 313– 8. http://dx.doi.org/10.1016/j.vaccine.2012.11.008 23153442 PMC3557524 · DOI
  62. [65]Azoulay E, Timsit J-F, Tafflet M, de Lassence A, Darmon M, Zahar J-R, et al Candida Colonization of the Respiratory Tract and Subsequent Pseudomonas Ventilator-Associated Pneumonia. Chest. 2006; 129(1): 110– 7. https://doi.org/10.1378/chest.129.1.110 16424420 · DOI
  63. [66]Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance. Clinical Infectious Diseases. 2015; 60(9): 1295– 303. doi: 10.1093/cid/civ048 25632010 PMC4462660 · DOI
  64. [67]Dafopoulou K, Xavier BB, Hotterbeekx A, Janssens L, Lammens C, Dé E, et al Colistin-Resistant Acinetobacter baumannii Clinical Strains with Deficient Biofilm Formation. Antimicrobial Agents and Chemotherapy. 2016; 60(3): 1892– 5. doi: 10.1128/AAC.02518-15 26666921 PMC4776000 · DOI
  65. [68]Yeaman MR, H JP Jr. Innovative Approaches to Improve Anti-Infective Vaccine Efficacy. Annual Review of Pharmacology and Toxicology. 2017; 57(1): 189– 222. doi: 10.1146/annurev-pharmtox-010716-104718 28061685 · DOI
  66. [69]Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, et al Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 2000; 406: 959 https://www.nature.com/articles/35023079#supplementary-information. 10984043
  67. [70]Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics. 1993; 134(3): 717– 28. 8349105 PMC1205510
  68. [73]Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr., Mowat E, Ramage G, et al A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc. 2008; 3(9): 1494– 500. doi: 10.1038/nport.2008.141 18772877 PMC2741160 · DOI · Paper page
  69. [74]Uppuluri P, Lopez-Ribot JL. An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence. 2010; 1(6): 483– 7. doi: 10.4161/viru.1.6.13186 21178492 PMC3073357 · DOI
  70. [75]Molloy MP, Herbert BR, Slade MB, Rabilloud T, Nouwens AS, Williams KL, et al Proteomic analysis of the Escherichia coli outer membrane. Eur J Biochem. 2000; 267(10): 2871– 81. 10806384
  71. [76]Soares NC, Cabral MP, Parreira JR, Gayoso C, Barba MJ, Bou G. 2-DE analysis indicates that Acinetobacter baumannii displays a robust and versatile metabolism. Proteome Sci. 2009; 7: 37 doi: 10.1186/1477-5956-7-37 19785748 PMC2761859 · DOI
  72. [77]Pitarch A, Jimenez A, Nombela C, Gil C. Decoding serological response to Candida cell wall immunome into novel diagnostic, prognostic, and therapeutic candidates for systemic candidiasis by proteomic and bioinformatic analyses. Mol Cell Proteomics. 2006; 5(1): 79– 96. Epub 2005/10/01. doi: 10.1074/mcp.M500243-MCP200 16195222 · DOI
  73. [78]Pitarch A, Pardo M, Jimenez A, Pla J, Gil C, Sanchez M, et al Two-dimensional gel electrophoresis as analytical tool for identifying Candida albicans immunogenic proteins. Electrophoresis. 1999; 20(4–5): 1001– 10. Epub 1999/05/27. doi: 10.1002/(SICI)1522-2683(19990101)20:4/5<1001::AID-ELPS1001>3.0.CO;2-L 10344278 · DOI
  74. [79]Liu M, Spellberg B, Phan QT, Fu Y, Lee AS, Edwards JE Jr., et al The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 120(6): 1914– 24. Epub 2010/05/21. doi: 10.1172/JCI42164 20484814 PMC2877958 · DOI
  75. [80]Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr., Ibrahim AS. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2004; 48(5): 1908– 11. doi: 10.1128/AAC.48.5.1908-1911.2004 15105158 PMC400587 · DOI
  76. [81]Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modelling, prediction and analysis. Nature protocols. 2015; 10(6): 845– 58. doi: 10.1038/nprot.2015.053 25950237 PMC5298202 · DOI · Paper page
  77. [82]Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nature methods. 2015; 12(1): 7– 8. doi: 10.1038/nmeth.3213 25549265 PMC4428668 · DOI · Paper page
  78. [83]Xu D, Zhang Y. Ab Initio Protein Structure Assembly Using Continuous Structure Fragments and Optimized Knowledge-based Force Field. Proteins. 2012; 80(7): 1715– 35. doi: 10.1002/prot.24065 22411565 PMC3370074 · DOI
  79. [85]Smith TF, Waterman MS. Identification of common molecular subsequences. Journal of Molecular Biology. 1981; 147(1): 195– 7. https://doi.org/10.1016/0022-2836(81)90087-5. 7265238 · DOI
  80. [86]Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al UCSF Chimera—A visualization system for exploratory research and analysis. Journal of Computational Chemistry. 2004; 25(13): 1605– 12. doi: 10.1002/jcc.20084 15264254 · DOI
  81. [87]Higgins DG, Sharp PM. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene. 1988; 73(1): 237– 44. https://doi.org/10.1016/0378-1119(88)90330-7. 3243435 · DOI

Cited by

Sorted by citations

Authors
Uppuluri, P., Lin, L., Alqarihi, A., Luo, G., Youssef, E. G., Alkhazraji, S., Yount, N. Y., Ibrahim, B. A., Bolaris, M. A., Edwards, J. E., Swidergall, M., Filler, S. G., Yeaman, M. R., & Ibrahim, A. S.
Affiliations
  • University of California, Los Angeles (US)
  • Beni-Suef University (EG)
Corresponding author
Ibrahim, Ashraf S.
ORCID
Venue
PLOS Pathogens
Publisher
Public Library of Science (PLoS)
Published
2018-05-10
Volume
14
Issue
5
Pages
e1007056
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
DOI
10.1371/journal.ppat.1007056
PMC
PMC5963808
OpenAlex
W2800960099
Cited by
57
References
5
Citations by year
2026: 2 · 2025: 8 · 2024: 4 · 2023: 11 · 2022: 12 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 1
FWCI
3.78
Type
journal article
Language
en
Update notices
new_version (2018-05-22)
Open access
Licence
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Greater South Information System
Funders
National Institute of Allergy and Infectious Diseases (AI 119339; AI 063382)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
Keywords
Candida albicans, Acinetobacter baumannii, immunotherapy targets, recombinant antigen, passive immunization, active immunization, polymicrobial biofilms, iron starvation, candidemia, bacteremia, pneumonia, immunocompromised patients, multidrug resistance
MeSH terms
Acinetobacter, Acinetobacter Infections, Animals, Anti-Bacterial Agents, Antibodies, Bacterial, Bacteria, Bacterial Infections, Bacterial Outer Membrane Proteins, Bacterial Vaccines, Candida albicans, Fungal Proteins, Immunization, Passive, Immunotherapy, Mice, Inbred BALB C, Vaccination, Biofilms, Acinetobacter baumannii, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review